Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

, is low blood sugar (hypoglycemia), which may be serious.  Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision.  Severe hypoglycemia may be serious and life threatening.  It may cause harm to your heart or brain.  Other possible side effects may include injection site reactions, including changes in fat tissue at the injection site, and allergic reactions, including itching and rash.  In rare cases, some allergic reactions may be life threatening.

Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works.  Before starting Lantus, tell your doctor about all your medical conditions including if you have liver or kidney problems, are pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed.

For full prescribing information, visit http://products.sanofi.us/lantus/lantus.html.

About Diabetes Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterized by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin being produced. Type 1 and type 2 diabetes are characterized by an increase in blood glucose concentrations (hyperglycemia). Over time, uncontrolled hyperglycemia leads to the macrovascular and microvascular complications of diabetes. Macrovascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Microvascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). The global incidence of diabetes is growing at an alarming rate, wit
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015   ndd Medical Technologies ... (PFT) that employs precise ultrasound technology, announced that its ... held by the San Antonio Pulmonary Fibrosis Support Group. ... or pulmonary fibrosis (PF), as well as those suspected ... footprint of a mere 12 square inches, EasyOne Pro ...
(Date:3/5/2015)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, today announced the appointment of several ... panel of experts will provide support for planning ... the company pipeline of novel investigational therapies to ... range of areas including opioid receptors, addiction, psychiatry, ...
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, Inc. ... that it has acquired the approved abbreviated new ... 50mg, 100mg and 150mg, previously marketed by Teva ... for this product was approximately $39 million in ... , President and CEO of ANI Pharmaceuticals, stated, ...
Breaking Medicine Technology:ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... Phase III data shows significant antitumor benefit in patients ... Early data show that at eight weeks of treatment, ... patients with advanced liver cancer - New data ... better cognitive function than those taking tamoxifen - ...
... May 27 Researchers have discovered a novel molecular path ... , a disease that mainly affects women and slowly ... finding, significant because it is a first step toward developing ... the June 11, 2009, issue of the New ...
Cached Medicine Technology:Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 2Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 3Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 4Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 5Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 6Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 7Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 8Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 9Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 10Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 11Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 12Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 13Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 14Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 15Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 16Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 17Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 18Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 2Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 3Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 4
(Date:3/6/2015)... As the Mayo Clinic's 2012 published ... & Associates Nationwide Legal Services, A.P.C., comments on these ... Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in ... “In light of a recently filed lawsuit, Ford & ... and explore the Mayo Clinic's Benicar case study findings ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as host to ... include the following activities:, October 5: ... 6: Conference Day 1, ending with a Fashion Show and ... with Local Entertainment and Dinner , October 8: ... , October 9-10: Textiles in India Tour (optional; ...
(Date:3/5/2015)... (PRWEB) March 06, 2015 The global digital PCR ... 2019, at CAGR of 7.8% from 2014 to 2019. , The ... at a CAGR of 7.8% from 2014 to 2019. Although the ... larger shares in the digital PCR (dPCR) and qPCR market the ... 10.7% in the forecast period. The growth of the digital PCR ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... dangerous levels of formaldehyde in low-cost laminate ... Bamboo, the leading manufacturer of eco-friendly building materials ... to customer safety by testing all their flooring ... leading emissions detection laboratory Benchmark International ...
(Date:3/5/2015)... FL (PRWEB) March 05, 2015 ... company focused on the peripheral nerve repair market, reported ... ended December 31, 2014 compared to $2.98 million in ... of its growth strategies. , “Our strong fourth ... our peripheral nerve repair products which is driving increased ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... the past decade, Asia has been the preferred destination ... medical treatments. The increase is partially due to high ... and United Kingdom. Specialized treatments, surgeries and therapies are ... cost, yet with bigger perks when it comes to ...
... Amber Court ( http://www.AmberCourtAL.com ) reaffirms its ... Public Advocate Ronald K. Chen,s investigation of Wisconsin-based Assisted ... depleted their personal savings. , ... of Amber Court Assisted Living ...
... April 21 When Gundersen Lutheran Health System set out ... to 2 percent decrease that,s common at healthcare facilities. Instead, ... less than two years. That,s 9,600 metric tons of carbon ... equivalent of removing 1,631 cars from the road. The La ...
... receive Magnet re-designation.DALLAS, April 21 The American ... Baylor University Medical Center at Dallas (Baylor ... effective immediately. Fewer than six percent of hospitals ... and merely two percent of the nation,s hospitals ...
... (BRONX, NY) Recurrent and metastatic endometrial and ... have spread to other organs and typically have developed ... chemotherapy may not be able to endure more chemo. ... Yeshiva University have shown that a combination of two ...
... Blue Cross and Blue Shield of Minnesota and ... financial results for 2008. The organization reported an overall ... revenues of $8.8 billion, with $8.0 billion paid to ... deficit was the result of net realized capital losses ...
Cached Medicine News:Health News:Medical Tourism is Good Therapy for the Hotel Industry 2Health News:Medical Tourism is Good Therapy for the Hotel Industry 3Health News:Medical Tourism is Good Therapy for the Hotel Industry 4Health News:Medical Tourism is Good Therapy for the Hotel Industry 5Health News:Amber Court Assisted Living Communities Reaffirms its Commitment to Seniors on Medicaid 2Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Blue Cross and Blue Shield of Minnesota Releases 2008 Financial Results 2
... The Finnpipette Digital offers improved ... The rounded handle, modified grippy finger ... enhance operator comfort and efficiency. Finnpipette ... with power-boosted gearing mechanism (pat. pend.) ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases....
Medicine Products: